To determine the roles of hepsin in prostate cancer prognosis, the TCGA prostate cancer survival data (550 cases) were analyzed, showing that higher expression of hepsin was slightly associated with a shorter survival time, including overall survival, disease-specific survival, disease-free survival, and progression-free survival. This evidence concerns the gene HPN and prostate carcinoma.